Shree Ganesh Remedies Ltd

- The company has invested significantly in R&D, infrastructure, and capacity over the last two years, focusing on projects they anticipate will commercialize in the near future. - CapEx remains aggressive with ongoing construction of manufacturing Block 9 near Plant 8, and a new pilot plant near Plant 4 to support advanced chemistries including flow chemistry. - Planned CapEx for FY26 is approximately ₹15 crore, mainly for manufacturing blocks and pilot plant. - Development of common infrastructure and utilities at the Dahej site is underway to support large-scale CRAMS projects. - Expansion at the Ankleshwar site is preferred for manufacturing infrastructure with ample space after acquiring neighboring land. - Strategic investment supports new technologies and equipment necessary for complex specialty chemical projects, including flow and other advanced chemistries. - A 2.5 MW solar power park was recently commissioned, contributing up to 70% of electricity from renewable sources, underlining commitment to sustainable manufacturing.

- Current revenue is approximately ₹109 crore, with 15-20% from CRAMS projects. - Revenue is expected to double over the next 3-4 years, driven largely by CRAMS and new projects. - CRAMS revenue will increase steadily, potentially doubling or tripling in the future. - No single project contributes ₹100 crore currently; peak revenues for key projects are around ₹30-35 crore annually. - Larger scale projects with volumes above 200-500 metric tons are in the pipeline, supporting growth. - FY26 is expected to be a consolidation year with moderate top-line growth and margin normalization. - CRAMS commercialization and approvals anticipated to support commercial supplies starting from mid-FY26 onwards. - Base business (pharma intermediates and specialty chemicals) projected to grow at mid-teens CAGR over the medium term. - Investments in R&D, capacity-building, and new chemistries are aligned with anticipated project demands to support future scale-up.

- FY26 is expected to be a year of consolidation with moderate top-line growth and margin normalization to 24-26% range due to pricing pressures and ramp-up costs. - Revenue growth is projected at a moderate pace rather than drastic increase in FY26. - Over the next 3-4 years, revenue is expected to double driven by growth in CRAMS projects and new product commercialization with a targeted CAGR of 20-25%. - New large-scale CRAMS projects with high-volume (>200 tons) and customer-specific custom synthesis are key growth drivers. - Infrastructure and R&D investments are anticipated to enable accelerated and profitable growth beyond FY26. - Profitability will improve as new manufacturing capacities become better utilized and higher margin CRAMS volumes ramp up. - EPS growth will follow revenue and margin expansion as commercial supplies from CRAMS projects commence, especially in FY27-29 timeframe.

- The company is actively working on multiple custom synthesis (crams) projects, with 6 projects typically closed in the lab annually. - Current crams revenue is approximately 15-20% of total revenue, expected to grow steadily over the next few years. - The order book includes projects with peak volumes above 200 metric tons; e.g., agrochemical and Japanese projects targeting 250-500+ metric tons. - New innovative multi-step complex products are in development with a few projects expected to generate annual revenues of 30-35+ crore at peak. - No single project currently expected to add 100 crore in FY27; growth anticipated through a portfolio of small-to-medium projects. - FY26 is seen as a consolidation year with capacity building and approvals underway, preparing for commercial supply ramp-up in FY27-28. - The Dahej site is being developed with utilities and infrastructure to support large-scale projects as firm orders materialize.

- There is no mention of any current or planned fundraising through debt or equity in the transcript. - The company is funding its strategic investments, including infrastructure and capacity expansions, through internal accruals. - The focus is on operational consolidation and capacity building in FY26 with approximate CapEx of around ₹15 crore. - No indications were given about raising external capital; emphasis is on financial prudence and using internal resources for growth initiatives.